Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Original Article

    Chromatography Assisted Validation of Alternate Plant Materials in a Polyherbal Formulation: A Prospective Positive Substitution

    wadmin1By wadmin1April 1, 2021Updated:August 5, 2021No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    Sunita Shailajan1,*, Swati Singh1, Sasikumar Menon2
    1Herbal Research Lab (Industrial Co-ordination Centre), Ramnarain Ruia Autonomous College, Matunga, Mumbai, Maharashtra, INDIA.
    2Therapeutic Drug Monitoring Laboratory, Sion (East), Mumbai, Maharashtra, INDIA.

    Pharmacognosy Communications,2021,11,2,127-132.
    DOI:10.5530/pc.2021.2.23
    Published: April 2021
    Type: Original Article

    ABSTRACT

    Introduction: Bergenia ligulata Wall. is a popular medicinal herb from family Saxifragaceae, belonging to category of medicinal plants, the authentic species of which are not available easily. Though Ayurvedic Formulary of India prescribes the use of Bergenia ligulata, manufacturers have been using different species of Bergenia in many traditional Ayurvedic formulations including Pushyanuga churna (PC). Commercial exploitation of Bergenia ligulata has resulted in imbalance between supplies of this plant drug as compared to its demand. Commercially therefore, Bergenia ciliata which is more abundantly available, is substituted for Bergenia ligulata. Methods: The present study was undertaken to validate the use of Bergenia ciliata in a polyherbal formulation (PC), as a positive substitute for Bergenia ligulata. One in-house PC containing B. ligulata, along with two commercially available formulations of PC containing different species of Bergenia were compared for their bergenin content using validated HPLCmethod to evaluate the phytochemical equivalence. Results: Bergenin content in the in-house formulation containing B. ligulata was found to be 0.27mg/gm whereas the commercial samples containing B. ciliata contained 0.24mg/gm of bergenin while another marketed formulation without label claim contained 0.162mg/gm of bergenin. The results clearly support the use of B. ciliata as a positive substitute for B. ligulata in PC. Conclusion: Positive substitution can be adopted by manufacturing units for the medicinal plant ingredients, which are scarcely available, to prevent their over-exploitation from the wild. Such substitutions can be justified if phytochemical equivalence could be demonstrated by validated chromatographic techniques. Nevertheless, evidence based efficacy studies need to be conducted additionally to corroborate such usage.

    Key words: Bergenia ligulata, Pushyanuga churna, Bergenin, Disputed drugs, Substitution, HPLC.

    Download PDF
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up